{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T02:59:33Z","timestamp":1792551573074,"version":"4.5.0"},"reference-count":227,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015550","name":"Italian Government, Ministry of Health","doi-asserted-by":"publisher","award":["Ricerca Corrente L4\/10_25"],"award-info":[{"award-number":["Ricerca Corrente L4\/10_25"]}],"id":[{"id":"10.13039\/501100015550","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Colorectal cancer (CRC) is among the most prevalent malignancies worldwide, representing the second leading cause of cancer-related mortality and accounting for approximately 2 million new cases and nearly half a million deaths annually. Global age-standardized incidence rates are highest in Australia\/New Zealand and other Western countries, and lowest in parts of sub-Saharan Africa and South Asia, reflecting variations in demographics, lifestyle exposures, and screening practices. Colon cancer constitutes the larger fraction of CRC cases, with rectal cancer contributing substantially, and early-onset CRC (&lt;50 years) is increasing across both high-income and emerging regions. Established risk factors include age, hereditary syndromes, obesity, sedentary behavior, dietary patterns, metabolic disorders, and chronic inflammation, with notable distinctions between colon and rectal subsites. This narrative review provides a comprehensive overview of CRC epidemiology, molecular and genetic pathogenesis, staging, and modern therapeutic approaches, addressing colon and rectal cancers separately due to their distinct biology, clinical behavior, and treatment strategies. By integrating current knowledge on genetic drivers, systemic and local therapies, and patient stratification, the review aims to inform clinical practice, support clinical trial design, discuss ongoing challenges and future perspectives, and foster further research toward precision-guided management of CRC.<\/jats:p>","DOI":"10.3390\/cancers17213438","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T17:02:01Z","timestamp":1761670921000},"page":"3438","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Genetic, Epidemiological, Clinical, and Therapeutic Trajectories in Colon and Rectal Cancers"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9488-6057","authenticated-orcid":false,"given":"Maurizio","family":"Capuozzo","sequence":"first","affiliation":[{"name":"Pharmaceutical Department, Asl Napoli 3 Sud, Via Marittima 3, 80056 Ercolano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Picone","sequence":"additional","affiliation":[{"name":"Istituto Nazionale Tumori di Napoli, IRCCS \u201cG. Pascale\u201d, Via Mariano Semmola, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6431-8278","authenticated-orcid":false,"given":"Francesco","family":"Sabbatino","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Dentistry, University of Salerno, Via Salvador Allende, 43, 84081 Baronissi, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariachiara","family":"Santorsola","sequence":"additional","affiliation":[{"name":"Istituto Nazionale Tumori di Napoli, IRCCS \u201cG. Pascale\u201d, Via Mariano Semmola, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1853-9897","authenticated-orcid":false,"given":"Francesco","family":"Caraglia","sequence":"additional","affiliation":[{"name":"Department of Precision Medicine, University of Campania \u201cLuigi Vanvitelli\u201d, Via Luigi De Crecchio 7, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1682-3792","authenticated-orcid":false,"given":"Domenico","family":"Iervolino","sequence":"additional","affiliation":[{"name":"Clinical Statistics Department, Institute for Advanced Statistical Sciences, Via San Felice n. 16, 80036 Palma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3923-4889","authenticated-orcid":false,"given":"Roberto","family":"Sirica","sequence":"additional","affiliation":[{"name":"Centro AMES, Via Padre Carmine Fico 24, 80013 Casalnuovo di Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7154-1328","authenticated-orcid":false,"given":"Oreste","family":"Gualillo","sequence":"additional","affiliation":[{"name":"Laboratory of Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases, IDIS, Complexo Hospitalario Universitario de Santiago de Compostela, University of Santiago de Compostela, Traves\u00eda da Choupana s\/n, 15706 Santiago de Compostela, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giordana","family":"Di Mauro","sequence":"additional","affiliation":[{"name":"Department of Human Pathology \u201cG. Barresi\u201d, School of Specialization in Medical Oncology, Via Consolare Valeria 1, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Castiello","sequence":"additional","affiliation":[{"name":"Centro AMES, Via Padre Carmine Fico 24, 80013 Casalnuovo di Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Ianniello","sequence":"additional","affiliation":[{"name":"Centro AMES, Via Padre Carmine Fico 24, 80013 Casalnuovo di Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2646-1254","authenticated-orcid":false,"given":"Alessia Maria","family":"Cossu","sequence":"additional","affiliation":[{"name":"Department of Precision Medicine, University of Campania \u201cLuigi Vanvitelli\u201d, Via Luigi De Crecchio 7, 80138 Naples, Italy"},{"name":"Laboratory of Precision and Molecular Oncology, Biogem Scarl, Institute of Genetic Research, Contrada Camporeale, 83031 Ariano Irpino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5374-3527","authenticated-orcid":false,"given":"Angela","family":"Nebbioso","sequence":"additional","affiliation":[{"name":"Department of Precision Medicine, University of Campania \u201cLuigi Vanvitelli\u201d, Via Luigi De Crecchio 7, 80138 Naples, Italy"},{"name":"Program of Medical Epigenetics, Vanvitelli Hospital, Via Luigi De Crecchio 7, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7312-5387","authenticated-orcid":false,"given":"Lucia","family":"Altucci","sequence":"additional","affiliation":[{"name":"Department of Precision Medicine, University of Campania \u201cLuigi Vanvitelli\u201d, Via Luigi De Crecchio 7, 80138 Naples, Italy"},{"name":"Laboratory of Precision and Molecular Oncology, Biogem Scarl, Institute of Genetic Research, Contrada Camporeale, 83031 Ariano Irpino, Italy"},{"name":"Program of Medical Epigenetics, Vanvitelli Hospital, Via Luigi De Crecchio 7, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3093-5408","authenticated-orcid":false,"given":"Francesco","family":"Izzo","sequence":"additional","affiliation":[{"name":"Istituto Nazionale Tumori di Napoli, IRCCS \u201cG. Pascale\u201d, Via Mariano Semmola, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6969-4157","authenticated-orcid":false,"given":"Renato","family":"Patrone","sequence":"additional","affiliation":[{"name":"Istituto Nazionale Tumori di Napoli, IRCCS \u201cG. Pascale\u201d, Via Mariano Semmola, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6252-573X","authenticated-orcid":false,"given":"Andrea","family":"Belli","sequence":"additional","affiliation":[{"name":"Istituto Nazionale Tumori di Napoli, IRCCS \u201cG. Pascale\u201d, Via Mariano Semmola, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9837-9148","authenticated-orcid":false,"given":"Massimiliano","family":"Berretta","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, Via Consolare Valeria 1, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5236-3132","authenticated-orcid":false,"given":"Marco","family":"Cascella","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Dentistry, University of Salerno, Via Salvador Allende, 43, 84081 Baronissi, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8158-7509","authenticated-orcid":false,"given":"Francesco","family":"Perri","sequence":"additional","affiliation":[{"name":"Istituto Nazionale Tumori di Napoli, IRCCS \u201cG. Pascale\u201d, Via Mariano Semmola, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Chiara","family":"Carrat\u00f9","sequence":"additional","affiliation":[{"name":"Istituto Nazionale Tumori di Napoli, IRCCS \u201cG. Pascale\u201d, Via Mariano Semmola, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guglielmo","family":"Nasti","sequence":"additional","affiliation":[{"name":"Istituto Nazionale Tumori di Napoli, IRCCS \u201cG. Pascale\u201d, Via Mariano Semmola, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8906-3785","authenticated-orcid":false,"given":"Massimo","family":"Di Maio","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Turin, AOU Citt\u00e0 della Salute e della Scienza di Torino, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5959-016X","authenticated-orcid":false,"given":"Antonio","family":"Giordano","sequence":"additional","affiliation":[{"name":"Sbarro Institute for Cancer Research and Molecular Medicine and Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA 19122, USA"},{"name":"Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5274-3989","authenticated-orcid":false,"given":"Giovanni","family":"Savarese","sequence":"additional","affiliation":[{"name":"Centro AMES, Via Padre Carmine Fico 24, 80013 Casalnuovo di Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2408-6091","authenticated-orcid":false,"given":"Michele","family":"Caraglia","sequence":"additional","affiliation":[{"name":"Department of Precision Medicine, University of Campania \u201cLuigi Vanvitelli\u201d, Via Luigi De Crecchio 7, 80138 Naples, Italy"},{"name":"Laboratory of Precision and Molecular Oncology, Biogem Scarl, Institute of Genetic Research, Contrada Camporeale, 83031 Ariano Irpino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2901-3855","authenticated-orcid":false,"given":"Alessandro","family":"Ottaiano","sequence":"additional","affiliation":[{"name":"Istituto Nazionale Tumori di Napoli, IRCCS \u201cG. Pascale\u201d, Via Mariano Semmola, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1136\/gutjnl-2022-327736","article-title":"Global burden of colorectal cancer in 2020 and 2040: Incidence and mortality estimates from GLOBOCAN","volume":"72","author":"Morgan","year":"2023","journal-title":"Gut"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"101131","DOI":"10.1016\/j.tranon.2021.101131","article-title":"Genetic regressive trajectories in colorectalcancer: A new hallmark of oligo-metastaticdisease?","volume":"14","author":"Ottaiano","year":"2021","journal-title":"Transl. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/s43018-024-00841-x","article-title":"Recapitulating the adenoma-carcinoma sequence by selection of four spontaneous oncogenic mutations in mismatch-repair-deficient human colon organoids","volume":"5","author":"Mizutani","year":"2024","journal-title":"Nat. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s10689-025-00460-0","article-title":"Genetics, genomics and clinical features of adenomatous polyposis","volume":"24","author":"Joo","year":"2025","journal-title":"Fam. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.32604\/or.2025.063951","article-title":"Lynch syndrome and colorectal cancer: A review of current perspectives in molecular genetics and clinical strategies","volume":"33","author":"Mateo","year":"2025","journal-title":"Oncol. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41392-024-01953-7","article-title":"Signaling pathways involved in colorectal cancer: Pathogenesis and targeted therapy","volume":"9","author":"Li","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.medj.2023.11.005","article-title":"Revolutionizing KRAS p.G12C therapy in metastatic colorectal cancer: The triumph of dual inhibition","volume":"4","author":"Ottaiano","year":"2023","journal-title":"Med"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1056\/NEJMoa2308795","article-title":"Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C","volume":"389","author":"Fakih","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Maiorano, B.A., Parisi, A., Maiello, E., and Ciardiello, D. (2022). The Interplay between Anti-Angiogenics and Immunotherapy in Colorectal Cancer. Life, 12.","DOI":"10.3390\/life12101552"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Sambo, M., Bailoni, A., Mariani, F., Granai, M., Calomino, N., Mancini, V., D\u2019Antiga, A., Montagnani, F., Tumbarello, M., and Lazzi, S. (2025). Prevalence, Incidence and Predictors of Anal HPV Infection and HPV-Related Squamous Intraepithelial Lesions in a Cohort of People Living with HIV. Diagnostics, 15.","DOI":"10.3390\/diagnostics15020198"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Bardel\u010d\u00edkov\u00e1, A., \u0160oltys, J., and Moj\u017ei\u0161, J. (2023). Oxidative Stress, Inflammation and Colorectal Cancer: An Overview. Antioxidants, 12.","DOI":"10.3390\/antiox12040901"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00384-024-04748-y","article-title":"Inflammatory bowel disease, colitis, and cancer: Unmasking the chronic inflammation link","volume":"39","author":"Shahgoli","year":"2024","journal-title":"Int. J. Color. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Burgos-Molina, A.M., T\u00e9llez Santana, T., Redondo, M., and Bravo Romero, M.J. (2024). The Crucial Role of Inflammation and the Immune System in Colorectal Cancer Carcinogenesis: A Comprehensive Perspective. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25116188"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3892\/ol.2024.14748","article-title":"Mechanism of APC truncation involved in colorectal cancer tumorigenesis (Review)","volume":"29","author":"Wang","year":"2024","journal-title":"Oncol. Lett."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Grant, A., Xicola, R.M., Nguyen, V., Lim, J., Thorne, C., Salhia, B., Llor, X., Ellis, N., and Padi, M. (2021). Molecular drivers of tumor progression in microsatellite stable APC mutation-negative colorectal cancers. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-02806-x"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Li, C., Furth, E.E., Rustgi, A.K., and Klein, P.S. (2023). When You Come to a Fork in the Road, Take It: WntSignaling Activates Multiple Pathways through the APC\/Axin\/GSK-3 Complex. Cells, 12.","DOI":"10.3390\/cells12182256"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2147\/CMAR.S411168","article-title":"Wnt\/\u03b2-Catenin Signaling Pathway in the Development and Progression of Colorectal Cancer","volume":"15","author":"He","year":"2023","journal-title":"Cancer Manag. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"djw332","DOI":"10.1093\/jnci\/djw332","article-title":"Multiple Roles of APC and its Therapeutic Implications in Colorectal Cancer","volume":"109","author":"Zhang","year":"2017","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s13045-020-00990-3","article-title":"Targeting the Wnt\/\u03b2-catenin signaling pathway in cancer","volume":"13","author":"Zhang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"20224","DOI":"10.1073\/pnas.1314239110","article-title":"Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974","volume":"110","author":"Liu","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1158\/1535-7163.MCT-19-0668","article-title":"Tankyrase Inhibitors Target Colorectal Cancer Stem Cells via AXIN-Dependent Downregulation of c-KIT Tyrosine Kinase","volume":"19","author":"Jang","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Huang, J.L., Chang, Y.T., Hong, Z.Y., and Lin, C.S. (2022). Targeting DNA Damage Response and Immune Checkpoint for Anticancer Therapy. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23063238"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Capuozzo, M., Santorsola, M., Bocchetti, M., Perri, F., Cascella, M., Granata, V., Celotto, V., Gualillo, O., Cossu, A.M., and Nasti, G. (2022). p53: From FundamentalBiology to Clinical Applications in Cancer. Biology, 11.","DOI":"10.3390\/biology11091325"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Liebl, M.C., and Hofmann, T.G. (2021). The Role of p53 Signaling in Colorectal Cancer. Cancers, 13.","DOI":"10.3390\/cancers13092125"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"104018","DOI":"10.1016\/j.critrevonc.2023.104018","article-title":"The prognosticrole of p53 mutations in metastatic colorectal cancer: A systematic review and meta-analysis","volume":"186","author":"Ottaiano","year":"2023","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/s41571-022-00671-9","article-title":"The current state of the art and future trends in RAS-targeted cancer therapies","volume":"19","author":"Punekar","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e902","DOI":"10.1093\/oncolo\/oyad117","article-title":"The Frequency of Specific KRAS Mutations, and Their Impact on Treatment Choice and Survival, in Patients with Metastatic Colorectal Cancer","volume":"28","author":"Torres","year":"2023","journal-title":"Oncologist"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"8","DOI":"10.2174\/1568026614666140423121525","article-title":"The Emerging Role of NRAS Mutations in Colorectal Cancer Patients Selected for Anti-EGFR Therapies","volume":"9","author":"Meriggi","year":"2014","journal-title":"Rev. Recent. Clin. Trials"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1186\/s13046-021-02130-2","article-title":"Resistance to anti-EGFR therapies in metastatic colorectal cancer: Underlying mechanisms and reversal strategies","volume":"40","author":"Zhou","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Ottaiano, A., Normanno, N., Facchini, S., Cassata, A., Nappi, A., Romano, C., Silvestro, L., De Stefano, A., Rachiglio, A.M., and Roma, C. (2020). Study of Ras Mutations\u2019 Prognostic Value in Metastatic Colorectal Cancer: STORIA Analysis. Cancers, 12.","DOI":"10.3390\/cancers12071919"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Ottaiano, A., Sabbatino, F., Perri, F., Cascella, M., Sirica, R., Patrone, R., Capuozzo, M., Savarese, G., Ianniello, M., and Petrillo, N. (2023). KRAS p.G12C Mutation in Metastatic Colorectal Cancer: Prognostic Implications and Advancements in Targeted Therapies. Cancers, 15.","DOI":"10.3390\/cancers15143579"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"R\u00edos-Hoyo, A., Monzon\u00eds, X., Vidal, J., Linares, J., and Montagut, C. (2024). Unveiling acquired resistance to anti-EGFR therapies in colorectal cancer: A long and winding road. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1398419"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Shan, H., Tian, G., Zhang, Y., and Qiu, Z. (2024). Exploring the molecular mechanisms and therapeutic potential of SMAD4 in colorectal cancer. Cancer Biol. Ther., 25.","DOI":"10.1080\/15384047.2024.2392341"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1158\/0008-5472.CAN-12-2706","article-title":"SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer","volume":"73","author":"Fleming","year":"2013","journal-title":"Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/his.14880","article-title":"Loss of function SMAD4 nonstop mutations in human cancer","volume":"82","author":"Bauer","year":"2023","journal-title":"Histopathology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1158\/1078-0432.CCR-18-1726","article-title":"SMAD4 Loss in Colorectal Cancer Patients Correlates with Recurrence, Loss of Immune Infiltrate, and Chemoresistance","volume":"25","author":"Wasserman","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1053\/j.gastro.2013.07.033","article-title":"Loss of SMAD4 from colorectal cancer cells promotes CCL15 expression to recruit CCR1+ myeloid cells and facilitate liver metastasis","volume":"145","author":"Itatani","year":"2013","journal-title":"Gastroenterology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1158\/1078-0432.CCR-16-0520","article-title":"Loss of SMAD4 Promotes Lung Metastasis of Colorectal Cancer by Accumulation of CCR1+ Tumor-Associated Neutrophils through CCL15-CCR1 Axis","volume":"23","author":"Yamamoto","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1053\/j.gastro.2014.03.052","article-title":"Loss of SMAD4 alters BMP signaling to promote colorectal cancer cell metastasis via activation of Rho and ROCK","volume":"147","author":"Voorneveld","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.1158\/0008-5472.CAN-22-1247","article-title":"SMAD4 Loss Induces c-MYC-Mediated NLE1 Upregulation to Support Protein Biosynthesis, Colorectal Cancer Growth, and Metastasis","volume":"82","author":"Loevenich","year":"2022","journal-title":"Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1517\/14728222.2013.782287","article-title":"Targeting TGF-\u03b2signaling in cancer","volume":"17","author":"Katz","year":"2013","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1158\/1541-7786.MCR-19-0525","article-title":"Targeting RICTOR Sensitizes SMAD4-Negative Colon Cancer to Irinotecan","volume":"18","author":"Wong","year":"2020","journal-title":"Mol. Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Nakayama, I., Hirota, T., and Shinozaki, E. (2020). BRAF Mutation in Colorectal Cancers: From Prognostic Marker to Targetable Mutation. Cancers, 12.","DOI":"10.3390\/cancers12113236"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00535-023-01955-2","article-title":"Prognostic role of detailed colorectal location and tumor molecular features: Analyses of 13,101 colorectal cancer patients including 2994 early-onset cases","volume":"58","author":"Ugai","year":"2023","journal-title":"J. Gastroenterol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4618","DOI":"10.1158\/1078-0432.CCR-21-2138","article-title":"Molecular Pathways and Mechanisms of BRAF in Cancer Therapy","volume":"28","author":"Poulikakos","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/oncolo\/oyab055","article-title":"BRAF Mutations Are Associated with Poor Survival Outcomes in Advanced-stage Mismatch Repair-deficient\/Microsatellite High Colorectal Cancer","volume":"27","author":"Tan","year":"2022","journal-title":"Oncologist"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1158\/2159-8290.CD-18-0125","article-title":"Advances on the BRAF Front in Colorectal Cancer","volume":"8","author":"Janku","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa2501912","article-title":"Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer","volume":"392","author":"Elez","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1093\/annonc\/mdy100","article-title":"Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer","volume":"29","author":"Siena","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s12094-019-02213-9","article-title":"Prevalence, prognosis and predictive status of HER2 amplification in anti-EGFR-resistant metastatic colorectal cancer","volume":"22","author":"Wang","year":"2020","journal-title":"Clin. Transl. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"oyaf158","DOI":"10.1093\/oncolo\/oyaf158","article-title":"Investigating incidence of RAS\/RAF and PIK3CA alterations in HER2-amplified colorectal cancer: A comprehensive analysis","volume":"30","author":"Cheng","year":"2025","journal-title":"Oncologist"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S1470-2045(23)00150-X","article-title":"Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): A multicentre, open-label, phase 2 study","volume":"24","author":"Strickler","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/14737140.2018.1442217","article-title":"Difference between right-sided and left-sided colorectal cancers: From embryology to molecular subtype","volume":"18","author":"Yang","year":"2018","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s12943-018-0923-9","article-title":"Comparative proteogenomic analysis of right-sided colon cancer, left-sided colon cancer and rectal cancer reveals distinct mutational profiles","volume":"17","author":"Imperial","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/nm.3967","article-title":"The consensus molecular subtypes of colorectalcancer","volume":"21","author":"Guinney","year":"2015","journal-title":"Nat. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"86356","DOI":"10.18632\/oncotarget.21169","article-title":"Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers","volume":"8","author":"Salem","year":"2017","journal-title":"Oncotarget"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"7303","DOI":"10.1158\/1078-0432.CCR-11-1570","article-title":"Gene expression differences between colon and rectum tumors","volume":"17","author":"Cordero","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Ciepiela, I., Szczepaniak, M., Ciepiela, P., Hi\u0144cza-Nowak, K., Kopczy\u0144ski, J., Macek, P., Kubicka, K., Chrapek, M., Tyka, M., and G\u00f3\u017ad\u017a, S. (2024). Tumor location matters, next generation sequencing mutation profiling of left-sided, rectal, and right-sided colorectal tumors in 552 patients. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-55139-w"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3393\/ac.2018.12.17","article-title":"Differences Regarding the Molecular Features and Gut Microbiota Between Right and Left Colon Cancer","volume":"34","author":"Kim","year":"2018","journal-title":"Ann. Coloproctol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3393\/ac.2019.03.17.1","article-title":"Immunological Differences Between Right-Sided and Left-Sided Colorectal Cancers: A Comparison of Embryologic Midgut and Hindgut","volume":"35","author":"Kwak","year":"2019","journal-title":"Ann. Coloproctol."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Paschke, S., Jafarov, S., Staib, L., Kreuser, E.D., Maulbecker-Armstrong, C., Roitman, M., Holm, T., Harris, C.C., Link, K.H., and Kornmann, M. (2018). Are Colon and Rectal Cancer Two Different Tumor Entities? A Proposal to Abandon the Term Colorectal Cancer. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19092577"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1056\/NEJMra012242","article-title":"Hereditary colorectal cancer","volume":"348","author":"Lynch","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S0140-6736(19)32319-0","article-title":"Colorectal cancer","volume":"394","author":"Dekker","year":"2019","journal-title":"Lancet"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/S1470-2045(15)00444-1","article-title":"Carcinogenicity of consumption of red and processed meat","volume":"16","author":"Bouvard","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Bocchetti, M., Ferraro, M.G., Ricciardiello, F., Ottaiano, A., Luce, A., Cossu, A.M., Scrima, M., Leung, W.Y., Abate, M., and Stiuso, P. (2021). The Role of microRNAs in Development of Colitis-Associated Colorectal Cancer. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22083967"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1080\/01635581.2023.2272343","article-title":"Beyond Body Size: Adiponectinas a Key Player in Obesity-Driven Cancers","volume":"75","author":"Capuozzo","year":"2023","journal-title":"Nutr. Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Ottaiano, A., Santorsola, M., Circelli, L., Perri, F., Cascella, M., Sabbatino, F., Capuozzo, M., Granata, V., Zappavigna, S., and Lombardi, A. (2023). Hypertension, type 2 diabetes, obesity, and p53 mutations negatively correlate with metastatic colorectal cancer patients\u2019 survival. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1091634"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2174\/1568009617666170330125619","article-title":"Obesity and Cancer: Biological Links and Treatment Implications","volume":"18","author":"Ottaiano","year":"2018","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.14309\/ajg.0000000000000803","article-title":"Smoking and Colorectal Cancer Risk, Overall and by Molecular Subtypes: A Meta-Analysis","volume":"115","author":"Botteri","year":"2020","journal-title":"Am. J. Gastroenterol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/ajcn\/86.3.556","article-title":"Obesity and colon and rectal cancer risk: A meta-analysis of prospective studies","volume":"86","author":"Larsson","year":"2007","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1093\/annonc\/mdq653","article-title":"Alcohol drinking and colorectalcancer risk: An overall and dose-response meta-analysis of published studies","volume":"22","author":"Fedirko","year":"2011","journal-title":"Ann. Oncol."},{"key":"ref_74","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1097\/CM9.0000000000003420","article-title":"Global esophageal cancer epidemiology in 2022 and predictions for 2050: A comprehensive analysis and projections based on GLOBOCAN data","volume":"137","author":"Qi","year":"2024","journal-title":"Chin. Med. J."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"101174","DOI":"10.1016\/j.tranon.2021.101174","article-title":"Global colorectal cancer burden in 2020 and projections to 2040","volume":"14","author":"Xi","year":"2021","journal-title":"Transl. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/s41416-023-02554-x","article-title":"Intratumoral presence of the genotoxic gut bacteria pks+ E. coli, Enterotoxigenic Bacteroides fragilis, and Fusobacterium nucleatum and their association with clinicopathological and molecular features of colorectal cancer","volume":"130","author":"Joo","year":"2024","journal-title":"Br. J. Cancer"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Ionescu, V.A., Diaconu, C.C., Gheorghe, G., Mihai, M.M., Diaconu, C.C., Bostan, M., and Bleotu, C. (2025). Gut Microbiota and Colorectal Cancer: A Balance Between Risk and Protection. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26083733"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1080\/09637486.2023.2290439","article-title":"Decreasing adherence to the Mediterranean diet: Health and environmental foe","volume":"74","author":"Godos","year":"2023","journal-title":"Int. J. Food Sci. Nutr."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1017\/S1368980013003169","article-title":"Mediterranean diet and health status: An updated meta-analysis and a proposal for a literature-based adherence score","volume":"17","author":"Sofi","year":"2014","journal-title":"Public Health Nutr."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Brusnic, O., Onisor, D., Boicean, A., Hasegan, A., Ichim, C., Guzun, A., Chicea, R., Todor, S.B., Vintila, B.I., and Anderco, P. (2024). Fecal Microbiota Transplantation: Insights into Colon Carcinogenesis and Immune Regulation. J. Clin. Med., 13.","DOI":"10.3390\/jcm13216578"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1136\/gutjnl-2015-310912","article-title":"Global patterns and trends in colorectal cancer incidence and mortality","volume":"66","author":"Arnold","year":"2017","journal-title":"Gut"},{"key":"ref_83","first-page":"233","article-title":"Colorectal cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Meng, Y., Tan, Z., Zhen, J., Xiao, D., Cai, L., Dong, W., and Chen, C. (2025). Global, regional, and national burden of early-onset colorectal cancer from 1990 to 2021: A systematic analysis based on the Global Burden of Disease Study 2021. BMC Med., 23.","DOI":"10.1186\/s12916-025-03867-9"},{"key":"ref_85","first-page":"89","article-title":"Epidemiology of colorectal cancer: Incidence, mortality, survival, and risk factors","volume":"14","author":"Rawla","year":"2019","journal-title":"Prz. Gastroenterol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1126\/science.aad2571","article-title":"The maternal microbiota drives early postnatal innate immune development","volume":"351","author":"Fuhrer","year":"2016","journal-title":"Science"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41385-020-0257-y","article-title":"Imprinting of the immune system by the microbiota early in life","volume":"13","author":"Eberl","year":"2020","journal-title":"Mucosal Immunol."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Gharib, E., and Robichaud, G.A. (2024). From Crypts to Cancer: A Holistic Perspective on Colorectal Carcinogenesis and Therapeutic Strategies. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25179463"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/0092-8674(90)90186-I","article-title":"A genetic model for colorectal tumorigenesis","volume":"61","author":"Fearon","year":"1990","journal-title":"Cell"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1046\/j.1365-2168.2002.02120.x","article-title":"The colorectal adenoma-carcinoma sequence","volume":"89","author":"Leslie","year":"2002","journal-title":"Br. J. Surg."},{"key":"ref_91","first-page":"19","article-title":"Genetic alterations in colorectal cancer","volume":"5","author":"Armaghany","year":"2012","journal-title":"Gastrointest. Cancer Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/359235a0","article-title":"APC mutations occur early during colorectal tumorigenesis","volume":"359","author":"Powell","year":"1992","journal-title":"Nature"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/418934a","article-title":"Tumorigenesis: RAF\/RAS oncogenes and mismatch-repair status","volume":"418","author":"Rajagopalan","year":"2002","journal-title":"Nature"},{"key":"ref_94","first-page":"7717","article-title":"p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis","volume":"50","author":"Baker","year":"1990","journal-title":"Cancer Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ccr.2012.02.022","article-title":"Accessories to the crime: Functions of cells recruited to the tumor microenvironment","volume":"21","author":"Hanahan","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/ng.3214","article-title":"A Big Bang model of human colorectal tumor growth","volume":"47","author":"Sottoriva","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12943-017-0596-9","article-title":"Epigenetics in cancer stem cells","volume":"16","author":"Toh","year":"2017","journal-title":"Mol. Cancer"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1750-1172-4-22","article-title":"Familial adenomatous polyposis","volume":"4","author":"Half","year":"2009","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/S0140-6736(13)61649-9","article-title":"Colorectal cancer","volume":"383","author":"Brenner","year":"2014","journal-title":"Lancet"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.acr.2022.03.001","article-title":"The pathologic diagnosis of carcinoma in various tissues","volume":"154","author":"Avery","year":"2022","journal-title":"Adv. Cancer Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1056\/NEJM199312303292701","article-title":"Prevention of colorectal cancer by colonoscopic polypectomy","volume":"329","author":"Winawer","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1038\/ajg.2017.174","article-title":"Colorectal cancer screening: Recommendations for physicians and patients from the US Multi-Society Task Force on Colorectal Cancer","volume":"112","author":"Rex","year":"2017","journal-title":"Am. J. Gastroenterol."},{"key":"ref_103","first-page":"119","article-title":"Genetic alterations underlying colorectal tumorigenesis","volume":"12","author":"Fearon","year":"1992","journal-title":"Cancer Surv."},{"key":"ref_104","first-page":"145","article-title":"Colorectal cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1053\/j.gastro.2012.06.001","article-title":"Guidelines for colonoscopy surveillance after screening and polypectomy: A consensus update by the US Multi-Society Task Force on Colorectal Cancer","volume":"143","author":"Lieberman","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1002\/(SICI)1097-0142(20000401)88:7<1739::AID-CNCR30>3.0.CO;2-T","article-title":"American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group","volume":"88","author":"Compton","year":"2000","journal-title":"Cancer"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Mikalonis, M., Avlund, T.H., and L\u00f8ve, U.S. (2024). Danish guidelines for treating acute colonic obstruction caused by colorectal cancer-a review. Front. Surg., 11.","DOI":"10.3389\/fsurg.2024.1400814"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1311194","article-title":"Multitarget stool DNA testing for colorectal-cancer screening","volume":"370","author":"Imperiale","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1001\/jama.2016.3332","article-title":"Screening for colorectal cancer: Updated evidence report and systematic review for the US Preventive Services Task Force","volume":"315","author":"Lin","year":"2016","journal-title":"JAMA"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1463-1318.2004.00585.x","article-title":"High compliance rates observed for follow up colonoscopy post polypectomy are achievableoutside of clinical trials: Efficacy of polypectomyisnotreduced by low compliance for follow up","volume":"6","author":"Colquhoun","year":"2004","journal-title":"Colorectal Dis."},{"key":"ref_111","first-page":"250","article-title":"Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society","volume":"68","author":"Wolf","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.7150\/ijms.97574","article-title":"Biological and Clinical Characteristics of Proximal Colon Cancer: Far from Its Anatomical Subsite","volume":"21","author":"Yang","year":"2024","journal-title":"Int. J. Med. Sci."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"359","DOI":"10.6004\/jnccn.2018.0021","article-title":"NCCN Guidelines Insights: Colon Cancer, Version 2.2018","volume":"16","author":"Benson","year":"2018","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Riihim\u00e4ki, M., Hemminki, A., Sundquist, J., and Hemminki, K. (2016). Patterns of metastasis in colon and rectal cancer. Sci. Rep., 6.","DOI":"10.1038\/srep29765"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/01.sla.0000217629.94941.cf","article-title":"Epidemiology and management of liver metastases from colorectal cancer","volume":"244","author":"Manfredi","year":"2006","journal-title":"Ann. Surg."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1186\/s12967-023-04460-5","article-title":"Metastasis organotropism in colorectal cancer: Advancing toward innovative therapies","volume":"21","author":"He","year":"2023","journal-title":"J. Transl. Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"438236","DOI":"10.1155\/2013\/438236","article-title":"Oligometastases\/Oligo-recurrence of lung cancer","volume":"2013","author":"Niibe","year":"2013","journal-title":"Pulm. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.radonc.2020.04.003","article-title":"Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document","volume":"148","author":"Lievens","year":"2020","journal-title":"Radiother. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.semradonc.2005.12.006","article-title":"Modeling growth kinetics and statistical distribution of oligometastases","volume":"16","author":"Withers","year":"2006","journal-title":"Semin. Radiat. Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"5028","DOI":"10.21037\/tcr-20-325","article-title":"Oligometastases: History and future vision of breast cancer","volume":"9","author":"Niibe","year":"2020","journal-title":"Transl. Cancer Res."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: A European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1016\/S1470-2045(12)70510-7","article-title":"Stereotactic body radiotherapy for oligometastases","volume":"14","author":"Tree","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S1470-2045(13)70447-9","article-title":"Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): Long-term results of a randomised, controlled, phase 3 trial","volume":"14","author":"Nordlinger","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.ctrv.2015.06.006","article-title":"Managing synchronous liver metastases from colorectal cancer: A multidisciplinary international consensus","volume":"41","author":"Adam","year":"2015","journal-title":"Cancer Treat. Rev."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1245\/s10434-012-2726-3","article-title":"Risk factors for survival after lung metastasectomy in colorectal cancer patients: A systematic review and meta-analysis","volume":"20","author":"Gonzalez","year":"2013","journal-title":"Ann. Surg. Oncol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.athoracsur.2007.02.093","article-title":"Surgical resection of pulmonary metastases from colorectal cancer: A systematic review of published series","volume":"84","author":"Pfannschmidt","year":"2007","journal-title":"Ann. Thorac. Surg."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.2003.04.187","article-title":"Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer","volume":"21","author":"Verwaal","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","article-title":"Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): A multicentre, randomized, open-label, phase 3 trial","volume":"22","author":"Quenet","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"604","DOI":"10.4251\/wjgo.v12.i6.604","article-title":"Real-world evidence on adjuvant chemotherapy in older adults with stage II\/III colon cancer","volume":"12","author":"Batra","year":"2020","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.annonc.2020.10.480","article-title":"Oxaliplatin-basedadjuvantchemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: The randomizedphase III ACHIEVE-2 trial","volume":"32","author":"Yamazaki","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1159\/000510258","article-title":"Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus Paper","volume":"43","author":"Bokemeyer","year":"2020","journal-title":"Oncol. Res. Treat."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Chang, C.L., Yuan, K.S., Wu, A.T.H., and Wu, S.Y. (2019). Adjuvant Therapy for High-Risk Stage II or III Colon Adenocarcinoma: A Propensity Score-Matched, Nationwide, Population-Based Cohort Study. Cancers, 11.","DOI":"10.3390\/cancers11122003"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1038\/s41591-025-03579-w","article-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial","volume":"31","author":"Tie","year":"2025","journal-title":"Nat. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1038\/s43018-025-00960-z","article-title":"Whole-exome tumor-agnostic ctDNA analysis enhances minimal residual disease detection and reveals relapse mechanisms in localized colon cancer","volume":"6","author":"Henriksen","year":"2025","journal-title":"Nat. Cancer"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"103015","DOI":"10.1016\/j.ctrv.2025.103015","article-title":"Advances in the management of locally advanced rectal cancer: A shift toward a patient-centred approach to balance outcomes and quality of life","volume":"140","author":"Airoldi","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"e2030097","DOI":"10.1001\/jamanetworkopen.2020.30097","article-title":"Total Neoadjuvant Therapy vs. Standard Therapy in Locally Advanced Rectal Cancer: A Systematic Review and Meta-analysis","volume":"3","author":"Kasi","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.hpb.2016.03.001","article-title":"Systematic review of systemic adjuvant, neoadjuvant and perioperative chemotherapy for resectable colorectal-liver metastases","volume":"18","author":"Khoo","year":"2016","journal-title":"HPB"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1200\/JCO.2005.00.349","article-title":"Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma","volume":"23","author":"Leonard","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Salihu, F., Corro, C., Ris, F., Meurette, G., Durham, A., Genoud, V., Bornand, A., Meyer, J., and Koessler, T. (Clin Color. Cancer, 2025). Impact of Neoadjuvant Immunotherapy in Localized Rectal Cancer. A Systematic Review, Clin Color. Cancer, in press.","DOI":"10.1016\/j.clcc.2025.08.005"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1093\/annonc\/mdv112","article-title":"Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: Results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest","volume":"26","author":"Cremolini","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/j.ejca.2015.06.116","article-title":"Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC)","volume":"51","author":"Heinemann","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.5306\/wjco.v15.i9.1136","article-title":"Colorectal cancer: Recent advances in management and treatment","volume":"15","author":"Fadlallah","year":"2024","journal-title":"World J. Clin. Oncol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1403108","article-title":"Initial therapy with FOLFOXIRI and bevacizumab for metastaticcolorectalcancer","volume":"371","author":"Loupakis","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S1470-2045(19)30862-9","article-title":"Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastaticcolorectalcancer (TRIBE2): A multicentre, open-label, phase 3, randomised, controlled trial","volume":"21","author":"Cremolini","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(12)70477-1","article-title":"Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): A randomised phase 3 trial","volume":"14","author":"Bennouna","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","article-title":"Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen","volume":"30","author":"Tabernero","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","article-title":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): A randomised, open-label, phase 3 trial","volume":"15","author":"Heinemann","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1001\/jama.2017.7105","article-title":"Effect of First-Line Chemotherapy Combined with Cetuximab or Bevacizumab on Overall Survival in Patients with KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial","volume":"317","author":"Venook","year":"2017","journal-title":"JAMA"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejca.2023.02.006","article-title":"Primarytumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: A systematic review and pooled analysis of randomised trials","volume":"184","author":"Rossini","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","article-title":"Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer","volume":"360","author":"Hitre","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41698-025-00892-y","article-title":"Multidimensional differences of right- and left-sided colorectal cancer and their impact on targeted therapies","volume":"9","author":"Pammer","year":"2025","journal-title":"NPJ Precis. Oncol."},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Kennel, K.B., and Greten, F.R. (2025). The immune microenvironment of colorectal cancer. Nat. Rev. Cancer, 1\u201320.","DOI":"10.1038\/s41568-025-00872-1"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Shiu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","article-title":"Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastaticcolorectalcancer","volume":"36","author":"Overman","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Cohen, R., Colle, R., Pudlarz, T., Heran, M., Duval, A., Svrcek, M., and Andr\u00e9, T. (2021). Immune Checkpoint Inhibition in Metastatic Colorectal Cancer Harboring Microsatellite Instability or Mismatch Repair Deficiency. Cancers, 13.","DOI":"10.3390\/cancers13051149"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S1470-2045(15)70127-0","article-title":"Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): A randomized, double-blind, multicentre, phase 3 study","volume":"16","author":"Tabernero","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/annonc\/mdy509","article-title":"Anti-EGFR-resistant clones decay exponentially after progression: Implications for anti-EGFR re-challenge","volume":"30","author":"Parseghian","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomized, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Ottaiano, A., Santorsola, M., Perri, F., Granata, V., Cascella, M., Sabbatino, F., and Nasti, G. (2023). Survival and Toxicities of Metastatic Colorectal Cancer Patients Treated with Regorafenib before TAS-102 or Vice Versa: A Mono-Institutional Real-Practice Study. J. Clin. Med., 12.","DOI":"10.3390\/jcm12020596"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S1470-2045(19)30827-7","article-title":"TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: An investigator-initiated, open-label, randomised, phase 2 trial","volume":"21","author":"Pfeiffer","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(16)00150-9","article-title":"Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12\/13 wild-type, HER2-positive metastaticcolorectalcancer (HERACLES): A proof-of-concept, multicentre, open-label, phase 2 trial","volume":"17","author":"Trusolino","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children","volume":"378","author":"Drilon","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1634\/theoncologist.2019-0129","article-title":"Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High\/Mismatch Repair-Deficient Metastatic Colorectal Cancer","volume":"24","author":"Morse","year":"2019","journal-title":"Oncologist"},{"key":"ref_167","first-page":"20200109","article-title":"Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)-directed treatment of peritoneal metastasis in end-stage colo-rectal cancer patients","volume":"5","author":"Graversen","year":"2020","journal-title":"Pleura Peritoneum"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"7814","DOI":"10.1245\/s10434-023-13941-2","article-title":"Safety and Efficacy of Oxaliplatin Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Colorectal and Appendiceal Cancer with Peritoneal Metastases: Results of a Multicenter Phase I Trial in the USA","volume":"30","author":"Raoof","year":"2023","journal-title":"Ann. Surg. Oncol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"102464","DOI":"10.1016\/j.tranon.2025.102464","article-title":"Treatment of colorectal peritoneal metastases with oxaliplatin induces biomarkers predicting response to immune checkpoint blockade","volume":"59","author":"Constantinides","year":"2025","journal-title":"Transl. Oncol."},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Ciappina, G., Toscano, E., Ottaiano, A., Capuozzo, M., Consolo, P., Maiorana, E., Carroccio, P., Franchina, T., Ieni, A., and Di Mauro, A. (2025). Negative Hyperselection in MetastaticColorectal Cancer for First-Line Anti-EGFR Therapy: A Narrative Review. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26052216"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/nm.3870","article-title":"Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients","volume":"21","author":"Siravegna","year":"2015","journal-title":"Nat. Med."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"e245635","DOI":"10.1001\/jamanetworkopen.2024.5635","article-title":"Anti-EGFR Rechallenge in Patients with Refractoryct DNA RAS\/BRAF wt Metastatic Colorectal Cancer: A Nonrandomized Controlled Trial","volume":"7","author":"Ciardiello","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1038\/s41591-022-01886-0","article-title":"Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: The phase 2 CHRONOS trial","volume":"28","author":"Pietrantonio","year":"2022","journal-title":"Nat. Med."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","article-title":"FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study","volume":"22","author":"Tournigand","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1200\/JCO.2007.14.9898","article-title":"Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil\/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer","volume":"26","author":"Cassidy","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_176","first-page":"256","article-title":"Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer","volume":"19","author":"Tosi","year":"2020","journal-title":"Clin. Color. Cancer"},{"key":"ref_177","first-page":"65","article-title":"HER2 as a Predictive Biomarker and Treatment Target in Colorectal Cancer","volume":"19","author":"Machiels","year":"2020","journal-title":"Clin. Color. Cancer"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/codi.16299","article-title":"Management of treatment-related sequelae following colorectal cancer","volume":"25","author":"Haas","year":"2023","journal-title":"Color. Dis."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/nrclinonc.2009.16","article-title":"Toxic effects and their management: Daily clinical challenges in the treatment of colorectal cancer","volume":"6","author":"Eng","year":"2009","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nrclinonc.2015.222","article-title":"Patient-reported outcomes in the evaluation of toxicity of anticancer treatments","volume":"13","author":"Basch","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_181","first-page":"4771","article-title":"EGFRI-associated health-related quality of life by severity of skin toxicity in metastatic colorectal cancer patients receiving epidermal growth factor receptor inhibitor target therapy","volume":"28","author":"Chiang","year":"2020","journal-title":"Support. Care Cancer"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1002\/cncr.25090","article-title":"Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life","volume":"116","author":"Joshi","year":"2010","journal-title":"Cancer"},{"key":"ref_183","first-page":"7855","article-title":"Neuropathy severity at the time of oxaliplatin treatment alteration in patients with colon cancer (Alliance A151912)","volume":"29","author":"Hertz","year":"2021","journal-title":"Support. Care Cancer"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S1470-2045(14)70106-8","article-title":"Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): A randomised phase 2 trial","volume":"15","author":"Wasan","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"e2333533","DOI":"10.1001\/jamanetworkopen.2023.33533","article-title":"Maintenance Therapy with Cetuximab After FOLFIRI Plus Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial","volume":"6","author":"Boige","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1200\/JCO.24.00979","article-title":"Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The IMPROVE Trial","volume":"43","author":"Avallone","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(07)61087-3","article-title":"Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): A randomised controlled trial","volume":"370","author":"Seymour","year":"2007","journal-title":"Lancet"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1200\/JCO.2014.59.4812","article-title":"Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer","volume":"33","author":"Lenz","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1093\/annonc\/mdu088","article-title":"Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX\/cetuximab or FOLFIRI\/cetuximab in a multidisciplinary concept (CELIM study)","volume":"25","author":"Folprecht","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12943-024-02063-2","article-title":"Clinical application of liquid biopsy in colorectal cancer: Detection, prediction, and treatment monitoring","volume":"23","author":"Tao","year":"2024","journal-title":"Mol. Cancer"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nrclinonc.2017.14","article-title":"Integrating liquid biopsies into the management of cancer","volume":"14","author":"Siravegna","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"e23914","DOI":"10.1016\/j.heliyon.2023.e23914","article-title":"Tackling the implementation gap for the uptake of NGS and advanced molecular diagnostics into healthcare systems","volume":"10","author":"Horgan","year":"2023","journal-title":"Heliyon"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1590\/S0100-879X2001000900001","article-title":"Irinotecan and oxaliplatin: An overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer","volume":"34","author":"Grivicich","year":"2001","journal-title":"Braz. J. Med. Biol. Res."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc1074","article-title":"5-fluorouracil: Mechanisms of action and clinical strategies","volume":"3","author":"Longley","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"ref_195","doi-asserted-by":"crossref","unstructured":"Chai, Y., Liu, J.L., Zhang, S., Li, N., Xu, D.Q., Liu, W.J., Fu, R.J., and Tang, Y.P. (2024). The effective combination therapies with irinotecan for colorectal cancer. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1356708"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1073\/pnas.0308716101","article-title":"Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients","volume":"101","author":"Wang","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/1476-4598-10-64","article-title":"New Topoisomerase I mutations are associated with resistance to camptothecin","volume":"10","author":"Gongora","year":"2011","journal-title":"Mol. Cancer"},{"key":"ref_198","doi-asserted-by":"crossref","unstructured":"Hu, H., Zhang, Q., Huang, R., Gao, Z., Yuan, Z., Tang, Q., Gao, F., Wang, M., Zhang, W., and Ma, T. (2021). Genomic Analysis Reveals Heterogeneity Between Lesions in Synchronous Primary Right-Sided and Left-Sided Colon Cancer. Front. Mol. Biosci., 8.","DOI":"10.3389\/fmolb.2021.689466"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1159\/000491778","article-title":"Distinguishable Prognostic Signatures of Left- and Right-Sided Colon Cancer: A Study Based on Sequencing Data","volume":"48","author":"Liang","year":"2018","journal-title":"Cell Physiol. Biochem."},{"key":"ref_200","doi-asserted-by":"crossref","unstructured":"Capuozzo, M., Ferrara, F., Santorsola, M., Zovi, A., and Ottaiano, A. (2023). Circulating Tumor Cells as Predictive and Prognostic Biomarkers in Solid Tumors. Cells, 12.","DOI":"10.3390\/cells12222590"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","article-title":"Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer","volume":"386","author":"Tie","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1001\/jamaoncol.2025.1646","article-title":"Early ctDNA and Survival in Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors: A Secondary Analysis of the SAMCO-PRODIGE 54 Randomized Clinical Trial","volume":"11","author":"Sullo","year":"2025","journal-title":"JAMA Oncol."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"102999","DOI":"10.1016\/j.ctrv.2025.102999","article-title":"Circulating tumor DNA as prognostic marker in patients with metastatic colorectal cancer undergoing systemic therapy: A systematic review and meta-analysis","volume":"139","author":"Holz","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"ref_204","doi-asserted-by":"crossref","unstructured":"Botticelli, A., Cremolini, C., Scagnoli, S., Biffoni, M., Lonardi, S., Fornaro, L., Guarneri, V., De Giorgi, U., Ascierto, P., and Blandino, G. (Clin. Cancer Res., 2025). The Impact of ConcordanceBetween Liquid and Tissue Biopsy for Actionable Mutations: Insights from the Rome Trial, Clin. Cancer Res., ahead of print.","DOI":"10.1158\/1078-0432.CCR-25-0430"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/s41587-021-00857-z","article-title":"SEQC2 Oncopanel Sequencing Working Group. Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology","volume":"39","author":"Deveson","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1158\/2159-8290.CD-20-0047","article-title":"Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade","volume":"10","author":"Zhang","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41467-020-14407-9","article-title":"Estimating growth patterns and driver effects in tumor evolution from individual samples","volume":"11","author":"Salichos","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"e00125","DOI":"10.1016\/j.plabm.2019.e00125","article-title":"Comparison of Roche Cell-Free DNA collection Tubes \u00ae to Streck Cell-Free DNA BCT \u00ae s for sample stability using healthy volunteers","volume":"16","author":"Parackal","year":"2019","journal-title":"Pract. Lab. Med."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3343\/alm.2023.0389","article-title":"Clinical Practice Guideline for Blood-based Circulating Tumor DNA Assays","volume":"44","author":"Lee","year":"2024","journal-title":"Ann. Lab. Med."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1093\/nar\/gkab274","article-title":"Argonaute integrated single-tube PCR system enables supersensitive detection of rare mutations","volume":"49","author":"Liu","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"ref_211","doi-asserted-by":"crossref","unstructured":"Pedrosa, L., Esposito, F., Thomson, T.M., and Maurel, J. (2019). The Tumor Microenvironment in Colorectal Cancer Therapy. Cancers, 11.","DOI":"10.3390\/cancers11081172"},{"key":"ref_212","doi-asserted-by":"crossref","unstructured":"Ottaiano, A., Ianniello, M., Santorsola, M., Ruggiero, R., Sirica, R., Sabbatino, F., Perri, F., Cascella, M., Di Marzo, M., and Berretta, M. (2023). From Chaos to Opportunity: Decoding Cancer Heterogeneity for Enhanced Treatment Strategies. Biology, 12.","DOI":"10.3390\/biology12091183"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1158\/2326-6066.CIR-15-0184","article-title":"Prospective Evaluation of Cetuximab-Mediated Antibody-Dependent Cell Cytotoxicity in Metastatic Colorectal Cancer Patients Predicts Treatment Efficacy","volume":"4","author":"Trotta","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/1479-5876-10-232","article-title":"Fc gamma receptor IIIa polymorphisms in advanced colorectal cancer patients correlated with response to anti-EGFR antibodies and clinical outcome","volume":"10","author":"Calemma","year":"2012","journal-title":"J. Transl. Med."},{"key":"ref_215","doi-asserted-by":"crossref","unstructured":"Ottaiano, A., Scala, S., Normanno, N., Napolitano, M., Capozzi, M., Rachiglio, A.M., Roma, C., Trotta, A.M., D\u2019Alterio, C., and Portella, L. (2019). Cetuximab, irinotecan and fluorouracile in fiRst-line treatment of immunologically-selected advanced colorectal cancer patients: The CIFRA study protocol. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-6109-z"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/bs.ircmb.2024.01.005","article-title":"Targeting KRAS and SHP2 signaling pathways for immunomodulation and improving treatment outcomes in solid tumors","volume":"386","author":"Sahu","year":"2024","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/cam4.2735","article-title":"Quantifying the impact of adherence to screening strategies on colorectal cancer incidence and mortality","volume":"9","author":"Ahnen","year":"2020","journal-title":"Cancer Med."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s11912-023-01361-0","article-title":"The Development of STING Agonists and Emerging Results as a Cancer Immunotherapy","volume":"25","author":"Hines","year":"2023","journal-title":"Curr. Oncol. Rep."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1146\/annurev-med-073118-011031","article-title":"Engineering IL-2 to Give New Life to T Cell Immunotherapy","volume":"72","author":"Overwijk","year":"2021","journal-title":"Annu. Rev. Med."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1038\/s41467-023-39224-8","article-title":"Bioengineering of bacteria for cancer immunotherapy","volume":"14","author":"Nguyen","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1200\/JCO.19.03296","article-title":"Regorafenib Plus Nivolumab in Patients with Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603)","volume":"38","author":"Fukuoka","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"101917","DOI":"10.1016\/j.eclinm.2023.101917","article-title":"Regorafenib plus nivolumab in patients with mismatch repair-proficient\/microsatellite stable metastatic colorectal cancer: A single-arm, open-label, multicentre phase 2 study","volume":"58","author":"Fakih","year":"2023","journal-title":"eClinicalMedicien"},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/s41467-024-45960-2","article-title":"Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort","volume":"15","author":"Saeed","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1200\/JCO.23.02728","article-title":"Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab with or Without Atezolizumab for Patients with Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study","volume":"42","author":"Antoniotti","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1200\/JCO.23.02736","article-title":"Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study","volume":"42","author":"Kawazoe","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_226","doi-asserted-by":"crossref","unstructured":"Cao, D., and Zhou, A. (2025). Tumor Immune Microenvironment and Current Status of Immune Checkpoint Inhibitor Therapy in Colorectal Cancer Liver Metastasis. Curr. Oncol., 32.","DOI":"10.3390\/curroncol32090493"},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1001\/jamaoncol.2024.3666","article-title":"Molecular, Socioeconomic, and Clinical Factors Affecting Racial and Ethnic Disparities in Colorectal Cancer Survival","volume":"10","author":"Yousef","year":"2024","journal-title":"JAMA Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/21\/3438\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T17:14:28Z","timestamp":1761671668000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/21\/3438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":227,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["cancers17213438"],"URL":"https:\/\/doi.org\/10.3390\/cancers17213438","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]}}}